Finanzen von Ionis Pharmaceuticals Inc (IONS)IONSIonis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. (IONS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Ionis core, accounting for 80.7% of total sales, equivalent to $234.34M. Other significant revenue streams include R&D revenue under collaborative agreements and Akcea Therapeutics. Understanding this composition is critical for investors evaluating how IONS navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Ionis Pharmaceuticals, Inc. maintains a gross margin of 98.98%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -38.18%, while the net margin is -40.30%. These profitability ratios, combined with a Return on Equity (ROE) of -105.50%, provide a clear picture of how effectively IONS converts its operational activities into shareholder value.

In the context of the broader market, IONS competes directly with industry leaders such as PRAX and SYRE. With a market capitalization of $7.52B, it holds a significant position in the sector. When comparing efficiency, IONS's gross margin of 98.98% stands against PRAX's N/A and SYRE's N/A. Such benchmarking helps identify whether Ionis Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Ionis Pharmaceuticals has shown volatile financial performance, with a gross margin of 98.98% in Q2 2026, but has faced significant net losses, including a net income loss of $114.65 million in the same quarter. The company's total revenue for Q2 2026 was $267.95 million, reflecting ongoing challenges in profitability despite high gross margins.